ASH (Ashland Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ASH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | ROBIN E. LAMPKIN | SVP, GC & Secretary | MIXED | — | — |
| 2026-08-05 | Peter T Thomas | Director | A | — | — |
| 2026-08-05 | ALLEN A SPIZZO | Director | A | — | — |
| 2026-07-30 | OSAMA M MUSA | SVP and CTO | M | — | — |
| 2026-07-29 | Alessandra Faccin Assis | SVP and GM, Life Sciences | MIXED | — | — |
| 2026-07-01 | Sanat Chattopadhyay | Director | A | — | — |
| 2026-07-01 | Steven D Bishop | Director | A | — | — |
| 2026-05-18 | BERTRAND LOY | Director | A | — | — |
| 2026-05-11 | JAMES P. MINICUCCI | SVP and GM, Personal Care | MIXED | — | — |
| 2026-04-01 | Steven D Bishop | Director | A | — | — |
| 2026-04-01 | Sanat Chattopadhyay | Director | A | — | — |
| 2026-02-10 | GUILLERMO NOVO | Chair of the Board and CEO | A | — | — |
| 2026-01-22 | Ashish K Kulkarni | Director | M | — | — |
| 2026-01-22 | Suzan F. Harrison | Director | A | — | — |
| 2026-01-21 | Scott Tozier | Director | A | — | — |
| 2026-01-21 | Jerome A Peribere | Director | A | — | — |
| 2026-01-21 | SUE MAIN | Director | A | — | — |
| 2026-01-21 | Sanat Chattopadhyay | Director | A | — | — |
| 2026-01-21 | Steven D Bishop | Director | A | — | — |
| 2026-01-05 | Sanat Chattopadhyay | Director | A | — | — |
| 2026-01-05 | Steven D Bishop | Director | A | — | — |
| 2025-11-21 | SAMUEL RICHARDSON | VP, Controller and PAO | A | — | — |
| 2025-11-21 | Eileen Drury | SVP and Chief HRO | A | — | — |
| 2025-11-21 | Dago Caceres | SVP & GM, Specialty Additives | A | — | — |
| 2025-11-21 | JAMES P. MINICUCCI | SVP and GM, Personal Care | A | — | — |
| 2025-11-21 | OSAMA M MUSA | SVP and CTO | A | — | — |
| 2025-11-21 | WILLIAM WHITAKER | SVP, CFO & PFO | A | — | — |
| 2025-11-21 | GUILLERMO NOVO | Chair of the Board and CEO | A | — | — |
| 2025-11-21 | ROBIN E. LAMPKIN | SVP, Gen Counsel and Secrty. | A | — | — |
| 2025-11-21 | Alessandra Faccin Assis | SVP and GM, Life Sciences | A | — | — |
| 2025-11-19 | ROBIN E. LAMPKIN | SVP, Gen Counsel and Secrty. | MIXED | — | — |
| 2025-11-19 | WILLIAM WHITAKER | SVP, CFO & PFO | MIXED | — | — |
| 2025-11-19 | SAMUEL RICHARDSON | VP, Controller and PAO | MIXED | — | — |
| 2025-11-19 | OSAMA M MUSA | SVP and CTO | MIXED | — | — |
| 2025-11-19 | OSAMA M MUSA | SVP and CTO | MIXED | — | — |
| 2025-11-19 | Eileen Drury | SVP and Chief HRO | MIXED | — | — |
| 2025-11-19 | GUILLERMO NOVO | Chair of the Board and CEO | MIXED | — | — |
| 2025-11-17 | SAMUEL RICHARDSON | VP, Controller and PAO | MIXED | — | — |
| 2025-11-17 | WILLIAM WHITAKER | SVP, CFO & PFO | MIXED | — | — |
| 2025-11-17 | Dago Caceres | SVP & GM, Specialty Additives | MIXED | — | — |
| 2025-11-17 | Alessandra Faccin Assis | SVP and GM, Life Sciences | MIXED | — | — |
| 2025-11-17 | JAMES P. MINICUCCI | SVP and GM, Personal Care | MIXED | — | — |
| 2025-11-17 | Eileen Drury | SVP and Chief HRO | MIXED | — | — |
| 2025-11-17 | GUILLERMO NOVO | Chair of the Board and CEO | MIXED | — | — |
| 2025-11-17 | ROBIN E. LAMPKIN | SVP, Gen Counsel and Secrty. | MIXED | — | — |
| 2025-10-02 | Sanat Chattopadhyay | Director | A | — | — |
| 2025-10-02 | Steven D Bishop | Director | A | — | — |
| 2025-07-28 | Alessandra Faccin Assis | SVP and GM, Life Sciences | MIXED | — | — |
| 2025-07-22 | WILLIAM WHITAKER | SVP, CFO & PFO | A | — | — |
| 2025-07-02 | Sanat Chattopadhyay | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 15,891,978 | — |
| — | 10%+ Owner | 13,311,981 | — |
| — | 10%+ Owner | 4,659,981 | — |
| — | Director | 4,083,978 | — |
| — | Director | 4,037,968 | — |
| — | SVP and CFO | 270,566 | — |
| — | Chair of the Board and CEO | 172,143 | — |
| — | Chief Executive Officer | 125,406 | — |
| — | Senior Vice President | 123,206 | — |
| — | Senior Vice President | 62,882 | — |
| — | Vice President | 57,584 | — |
| — | Chief Financial Officer | 54,045 | — |
| — | Senior Vice President | 52,226 | — |
| — | Director | 41,984 | — |
| — | Senior Vice President | 41,532 | — |
| — | SVP and CTO | 30,806 | — |
| — | Senior Vice President | 30,589 | — |
| — | Chief Executive Officer | 30,082 | — |
| — | VP, Finance & Prinpl Acctg Off | 22,319 | — |
| — | Sr. Vice President | 19,437 | — |
| — | Vice President | 18,887 | — |
| — | Senior Vice President | 16,034 | — |
| — | Vice President | 14,198 | — |
| — | Chief Financial Officer | 13,227 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASH quote page; the site-wide leaderboard is on the insider transactions hub.